GE-CAT - German Evaluation of Cancer associated Thrombosis A prospective register trial for patients with hematological and oncological diseases and venous thromboembolism in Berlin

A. Jühling, M. Sinn, E. T. Wolter, S. Bischoff, U. Pelzer, L. Wislocka, J. K. Striefler, F. Brandes, H. Riess, R. Klamroth (Berlin, Germany)

Venous thrombosis
Date: 17.02.2017,
Time: 17:15 - 18:15

Objective: Different recommendations for cancer patients with venous thromboembolism (VTE) exist. The recently published german S2-Guidelinine for diagnosis and treatment of venous thromboembolism recommend anticoagulation for 3 to 6 months preferably with low molecule weight heparin (LMWH). LMWH are actually estimated to be the most effective and safest treatment option in cancer patients with VTE (AWMF 10/2015). However, it remains unclear how cancer patients with VTE are treated in clinical care in Germany today. A recent published health service trial (Matzdorff A Oncol Res Treat 2016) was done in 2014 by a questionnaire. This survey reveals that practice patterns often do not follow the guideline recommendations. In former register trials, cancer patients were insufficiently characterized and their specific characteristics were inadequately discussed (Marchena PJ Thromb Haemost. 2012). Especially, only insufficient data of patient characteristics and anticoagulation regimens used are available, as well as informations about the mainly treating physicians. The GE-CAT register was set up for Berlins two main hospital companies Charité and Vivantes. Both together take care for about 375000 hospitalized patients per year, thus covering about 50 % of the in-ward health service of the Berlin region. Primary objective of this health services research is to evaluate the treatment reality of patients with cancer associated VTE in clinical daily practice. It will give results about the relative proportion of VTE patients with cancer and captures cancer-patients course of disease and treatment tracks for the first time.

Methods: GE-CAT is a prospective register trial with a duration of 3 years. Patient with an age of more than 18 years, a newly diagnosed VTE will be enrolled. Patients without a diagnosis of cancer are anonymously documented captured with a short basis assessment but without further follow-up. After signed written informed consent patients with the diagnosis of any kind of cancer will get a basis documentation by a physician. A follow up is scheduled after 3 and 6 months per telephone interview. Points of interest are: Rate of tumor associated thromboembolism, diagnostics and primary anticoagulation treatment, mortality, relapse of the venous thromboembolism or bleeding within 3 and 6 months, serious adverse events and determination of patients tracks.